If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
Here you can find information on the design of NOVELTY and its sub-studies.
NOVELTY is a global, prospective, observational study, which is following ~12,000 patients over 3 years.
Watch our short animation to learn more about the NOVELTY study, who is eligible to take part and what we hope to achieve
*A phenotype is an observable characteristic or trait of a disease, such as morphology, development, biochemical or physiological properties, without necessarily any implication of a mechanism.
†An endotype is a subtype of a condition, defined by a distinct functional or pathobiological mechanism.
In the Netherlands and Sweden, enrolment is underway for a sub-study examining respiratory tract biomarkers by nasal sampling. Protein biomarkers and gene expression from the samples will be interpreted alongside other NOVELTY biosamples, in addition to demographic and clinical characteristics. As of 15 March 2020, 153 patients have consented to enrolment in the study. Enrolment is due to begin later in 2020. For further information, please contact: AZNoveltyProject@astrazeneca.com
The ADPro sub-study in the UK aims to precisely characterise patients with asthma and/or COPD using magnetic resonance imaging (MRI), physiological and metabolic measures to assess small airways dysfunction. These techniques will enable investigation of the rate and pattern of disease progression in patients with different clinical features. For further information, please contact: AZNoveltyProject@astrazeneca.com